Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Amgen's Prolia Goes, So Goes The Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Wall Street analysts' reactions are mixed as to the meaning of an FDA advisory committee's mixed votes on Amgen's denosumab.

You may also be interested in...

Amgen's Mixed Advisory Committee Votes On Prolia Still Offer A Good Start

The Reproductive Health Drugs Advisory Committee backs Prolia's use to treat osteoporosis in postmenopausal women and bone loss in men undergoing hormone ablation therapy for prostate cancer - though not the largest indication of osteoporosis prevention as well as a REMS.

GSK Denosumab Deal Gives Amgen A Leg Up In Primary Care

Thanks to a new deal with GlaxoSmithKline for the marketing of its cherished bone drug denosumab outside the U.S. in post-menopausal osteoporosis, Amgen gets a much needed, solid launch pad for its first major venture into primary care

Amgen, GSK To Team Up On Denosumab Commercialization in Europe

Amgen's big bet on denosumab gets a boost from a Big Pharma partner in Europe, with U.S. rights intact.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts